Global orphan drug market is rise gradually to an estimated value of USD 326.25 billion by 2026 registering a CAGR of 8.5% in the forecast period of 2019-2026. Growing number of orphan diseases, accelerating novel therapies and orphan drug development programs and exclusive incentives from the government are the key factors for market growth
This Orphan Drug market research report is a resource, which provides current as well as upcoming technical and financial details of the industry for the forecast period. To improve customer experience while using this report, all the facts and figures of statistical and numerical data are represented very well. The report gives market definition in the form of market driving factors and market restraints which helps estimating the demand of particular product depending on several aspects. Expert solutions combined with potential capabilities make this Orphan Drug market report outshining for the businesses.
Get Sample Copy Of This Report+ All Related Graphs @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-orphan-drugs-market
Few of the major competitors currently working in the global orphan disease market are F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie, AstraZeneca, Baxter, Eli Lilly and Company, Johnson & Johnson Services Inc., Merck KGaA, Novo Nordisk A/S, Bristol-Myers Squibb Company, Alexion Pharmaceuticals, Kyowa Hakko Kirin Co., Ltd., Amgen Inc., Biogen, Celldex Therapeutics, GlaxoSmithKline plc., Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated (US) and among others.
Key Developments in the Market:
In August 2018, Kyowa Hakko Kirin Co., Ltd received the FDA approval for Poteligeo (mogamulizumab-kpkc) injection, an Orphan Drug, for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sezary syndrome which are the types of non-Hodgkin lymphoma
In August 2018, Takeda Pharmaceutical Company Limited received FDA approval for Takhzyro (lanadelumab-flyo) injection for the treatment to hereditary angioedema (HAE) attack in patients 12 years of age and older
In June, 2018, Ascendis Pharma A/S received the FDA Orphan Drug Designation for TransCon PTH for the treatment of hypoparathyroidism. TransCon PTH is a long acting parathyroid hormone replacement therapy which helps in restoring the activity of parathyroid hormone
Key Insights mentioned in the Orphan Drug research Report
- It provides overview of the industry with basic introduction to the market
- Comprises profiles of major companies operating in the Market
- Historical data, Current market size and Forecast up to 2026.
- Analysis like SWOT analysis, Porters Five Force Analysis and PESTLE Analysis are included in the report.
- Key top players of the market are covered in the report. it includes sales, revenue and market share of the analysis of the market by players, products and Applications.
Enquire Here Get customization & check discount for report @: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-orphan-drugs-market
Segmentation: Global Orphan Drug Market
By Disease Type
(Oncology disease, Metabolic Disease, Hepatology, Immunology, Infection, Neurology and Others),
Drug Type
(Biological, Non-Biological, and Others),
Indication Type
(Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Renal Cell Carcinoma and Others),
Drug class
(Lenalidomide, Rituximab, Glatiramer Acetate, Nivolumab, Interferon Beta-1a, Ibrutinib, Cinacalcet Hydrochloride, Imatinib Mesylate, Bortezomib, Sodium Oxybate and Others),
Therapy Type
(Medication, Surgery and Others),
Route of Administration
(Oral, Intravenous and Others),
End- users
(Hospitals, Homecare, Specialty Clinics, Others),
Geography
(North America, South America, Europe, Asia-Pacific, Middle East and Africa)
To know more about the study @ https://www.databridgemarketresearch.com/reports/global-orphan-drugs-market
About Data Bridge Market Research
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
